Skip to main content
Caplight Logo









Celosia Therapeutics

Celosia Therapeutics

Private
SydneyHealthcare & Life Scienceshttps://celosiatx.com/

Last Round

Series A

Nov 28, 2024

Total Funding Raised

$12.92M

Company Overview

Celosia Therapeutics is a biotechnology company that develops precision gene therapies for neurodegenerative diseases, including ALS, FTD, and Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyAAV-based gene therapyneurodegenerative diseaseALSAmyotrophic Lateral SclerosisFrontotemporal DementiaFTDprecision medicinebiotechdrug discoveryclinical stage biotechTDP-43genetic medicineclinical trialstherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Celosia Therapeutics Comparables

Compare Celosia Therapeutics with similar companies based on industry and business-model similarity.

Celosia Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avrion Therapeutics AG
85%
QurAlis
79%
VectorY Therapeutics
78%

Celosia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 28, 2024
SeedOct 31, 2022

Key People

Founding team and executive leadership

Lars Ittner

Chief Medical Officer, Co-Founder

Founding Team

Kathryn Sunn

Chief Executive Officer

Executive Team

Celosia Therapeutics Investors

Notable investors and investment history

Celosia Therapeutics investors
InvestorRounds
UniSuper ManagementSeries A
UniseedSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 28, 2024

    $11M round led by Uniseed.

  • Oct 31, 2022

    Raised $2M in seed funding.

Celosia Therapeutics Filings

Explore SEC and related filing metadata, where available.

Celosia Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Celosia Therapeutics's valuation, stock price, and market status.

Is Celosia Therapeutics a public or private company?

Celosia Therapeutics is a private company.

What is the current stock price of Celosia Therapeutics?

Celosia Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Celosia Therapeutics worth (valuation)?

Valuation information for Celosia Therapeutics is not publicly available.

Can I buy Celosia Therapeutics stock?

Celosia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Celosia Therapeutics's last funding round?

Celosia Therapeutics's most recent funding round was Series A on November 28, 2024.

Who are the main investors in Celosia Therapeutics?

Key investors in Celosia Therapeutics include Uniseed.

Will Celosia Therapeutics IPO soon?

No public IPO plans have been announced for Celosia Therapeutics.

How can I track Celosia Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Celosia Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSydney
Employee Range5
Year Founded2022
Last FundingNov 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?